ArticleAdvances in therapy2026
Effectiveness and Safety of Nefecon in Primary IgA Nephropathy Across Different Baseline Proteinuria Levels: A Real-World Study.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionIgA nephropathy (IgAN) is a chronic autoimmune kidney disease characterized by the deposition of immune complexes containing galactose-deficient IgA1 (Gd-IgA1) in the glomerulus. Nefecon is a targeted-release formulation of the budesonide that reduces excess production of Gd-IgA1. This study aimed to evaluate the real-world effectiveness and safety of nefecon across different baseline proteinuria levels in this disease population.
methodsIn this retrospective real-world study, 28 patients with IgAN who received nefecon for more than 9 months were consecutively included between September 2024 and March 2025. Data on demographics and clinical characteristics, outcomes, and safety were collected and analyzed.
resultsAfter 9 months of nefecon treatment, proteinuria reduced from 1.7 ± 1.2 to 0.6 ± 0.5 g/day (55.8% reduction), while estimated glomerular filtration rate improved from 80.3 ± 24.6 to 86.2 ± 25.4 mL/min/1.73 m
conclusionIn the real-world practice, nefecon was associated with favorable antiproteinuric and renal benefits with acceptable safety in patients with IgAN, including those with relatively low baseline proteinuria. This study suggests a potential benefit of early intervention following diagnosis.
Indexed as
Identifiers
42709324What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.